SCHEMBL23201962

SCHEMBL23201962

O=C(NO)c1cnc(Cn2c(N3CCOCC3)nc3ccccc32)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.49
HDAC6 Q9UBN7 4/20 0.49
HDAC3 O15379 3/20 0.49
HDAC2 Q92769 3/20 0.49
HDAC4 P56524 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC9 Q9UKV0 2/20 0.49
HDAC5 Q9UQL6 2/20 0.49
CYP2D6 P10635 4/20 0.43
HRH1 P35367 4/20 0.43
KCNH2 Q12809 2/20 0.43
SOS1 Q07889 1/20 0.42
CHRM1 P11229 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23203083 0.88 HDAC1 (0.44) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL23201976 0.83 HDAC6 (0.52) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL23167201 0.83 HDAC6 (0.70) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL29779589 0.83 HDAC6 (0.70) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL23202499 0.79 HDAC1 (0.52) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL23201982 0.73 HDAC6 (0.67) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL23167204 0.71 HDAC6 (0.56) HDAC1HDAC6HDAC3HDAC2HDAC8
SCHEMBL23167351 0.71 HDAC1 (0.56) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL29779620 0.71 HDAC1 (0.56) HDAC1HDAC6HDAC3HDAC2HDAC4
SCHEMBL23203541 0.70 HDAC6 (0.46) HDAC1HDAC6HDAC3HDAC2HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381148-A1 HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF TENAYA THERAPEUTICS, INC. 2023-11-30 US disclosed
US-20230381148-A1 HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF TENAYA THERAPEUTICS, INC. 2023-11-30 US disclosed
US-20230123856-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2023-04-20 US disclosed
WO-2021067859-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2021-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381148-A1 HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF HDAC6, HDAC1, HDAC2 HDAC1 2/4885HDAC6 1/4885HDAC3 4/4885
US-20230123856-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF SLC28A1, SLC5A1, SLC9A5 HDAC1 60/4885HDAC6 40/4885HDAC3 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.